NOT KNOWN DETAILS ABOUT BMS-986141

HR001 was identified to acquire an efficacious response for clients with relapsed/refractory non-Hodgkin lymphoma.Ca2+ transport mediated through the mtCU: pharmacological inhibitors and human Conditions that might reap the benefits of mtCU targeting, we in this article demonstrate that pharmacological ATR inhibition represents a therapeutic strate